Characteristics of CH in adults with HLH
| Characteristics . | Total cohort . | CHIP . | No CHIP . | P (CHIP vs no CHIP) . |
|---|---|---|---|---|
| Patients without myeloid malignancy, n | 80 | 21 | 59 | |
| Median age (IQR) | 52 (36.3-62.5) | 58 (50.5-69.5) | 48 (32-60) | .025* |
| Gender, n (%) | >.99 | |||
| Male | 43 (54) | 11 (52) | 32 (54) | |
| Female | 37 (46) | 10 (48) | 27 (46) | |
| Prior cytotoxic therapy, n (%) | .77 | |||
| Received | 20 (25) | 6 (29) | 14 (24) | |
| Never received | 60 (75) | 15 (71) | 45 (76) | |
| Specimen source, n (%) | .75 | |||
| Bone marrow | 64 (80) | 16 (76) | 48 (81) | |
| Peripheral blood | 16 (20) | 5 (24) | 11 (19) | |
| Lymphoid malignancy, n (%) | .20 | |||
| Present | 35 (44) | 12 (57) | 23 (39) | |
| Absent | 45 (56) | 9 (43) | 36 (61) |
| Characteristics . | Total cohort . | CHIP . | No CHIP . | P (CHIP vs no CHIP) . |
|---|---|---|---|---|
| Patients without myeloid malignancy, n | 80 | 21 | 59 | |
| Median age (IQR) | 52 (36.3-62.5) | 58 (50.5-69.5) | 48 (32-60) | .025* |
| Gender, n (%) | >.99 | |||
| Male | 43 (54) | 11 (52) | 32 (54) | |
| Female | 37 (46) | 10 (48) | 27 (46) | |
| Prior cytotoxic therapy, n (%) | .77 | |||
| Received | 20 (25) | 6 (29) | 14 (24) | |
| Never received | 60 (75) | 15 (71) | 45 (76) | |
| Specimen source, n (%) | .75 | |||
| Bone marrow | 64 (80) | 16 (76) | 48 (81) | |
| Peripheral blood | 16 (20) | 5 (24) | 11 (19) | |
| Lymphoid malignancy, n (%) | .20 | |||
| Present | 35 (44) | 12 (57) | 23 (39) | |
| Absent | 45 (56) | 9 (43) | 36 (61) |
Characteristics of patients in the cohort without myeloid malignancy, stratified by the presence or absence of CH. Cytotoxic therapy refers to the receipt of treatment directed at the malignancy associated with the HLH diagnosis.
*Fisher’s exact test.